BioMed Research International · 2015 · 14 citations · 23 references
Life SciencesGeneticsMolecular GeneticsMedical GeneticsMolecular NeurobiologyNeurogeneticsMolecular Basis Of NeurodegenerationNeurodegenerative Disease GeneticsNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseParkinsonian DisordersCell Survival AssaysFunctional AssaysLeucine-rich Repeat DomainsLeucine-rich Repeat Receptor-like KinasesLrrk2 MutationsParkinson's Disease GeneticsPathogenic EffectsPoint Mutations
Mutations in the leucine-rich repeat kinase 2 (LRRK2) have been known to be a major genetic component affecting Parkinson's disease (PD). However, the pathogenicity of many of the LRRK2 variants is unclear because they have been detected in single patients or also in patients and controls. Here, we selected 5 exonic variants (L1165P, T1410M, M1646T, L2063X, and Y2189C) from each of the protein domain of LRRK2 and analysed their possible association with pathogenicity using in vitro functional assays. Point mutations representing each of these variants were incorporated into the LRRK2 gene, and functional aspects such as the percentage of cell survival upon application of stress and kinase activity were measured. Our results showed that all 5 variants had a significantly negative effect on the survival of cells, in both presence and absence of stress, as compared to the wild-type. In addition, there was also a slight increase in kinase activity in most of the variants in comparison to the wild-type. A negative correlation between cell survival and kinase activity was observed. These data suggest that most of the variants despite being located in different domains of LRRK2 appear to exert a potential pathogenic effect possibly through an increased kinase activity, supporting a gain of function mechanism.
23
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Alexander Zimprich, Saskia Biskup, Petra Leitner et al. · Neuron · 2004 · 3.1K citations · Full text
A common LRRK2 mutation in idiopathic Parkinson's disease
William P. Gilks, Patrick M. Abou‐Sleiman, Sonia Gandhi et al. · The Lancet · 2005 · 778 citations · Full text
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio, Shushant Jain, Ann E. Kingsbury et al. · Neurobiology of Disease · 2006 · 748 citations · Full text
Kinase activity of mutant LRRK2 mediates neuronal toxicity
Wanli W. Smith, Zhong Pei, Haibing Jiang et al. · Nature Neuroscience · 2006 · 623 citations